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ABSTRACT 11 
Environmental mastitis is the most common and costly form of mastitis in modern dairy herds where 12 
contagious transmission of intramammary pathogens is controlled through implementation of 13 
standard mastitis prevention programs. Environmental mastitis can be caused by a wide range of 14 
bacterial species and binary classification of species as contagious or environmental is misleading, 15 
particularly for Staphylococcus aureus, Streptococcus uberis and other streptococcal species, 16 
including Streptococcus agalactiae. Bovine faeces, the indoor environment and used pasture are 17 
major sources of mastitis pathogens, including E. coli and S. uberis. A faeco-oral transmission cycle 18 
may perpetuate and amplify the presence of such pathogens, including Klebsiella pneumoniae and S. 19 
agalactiae. Because of societal pressure to reduce reliance on antimicrobials as tools for mastitis 20 
control, management of environmental mastitis will increasingly need to be based on prevention. 21 
This requires a reduction in environmental exposure through bedding, pasture and pre-milking 22 
management and enhancement of the host response to bacterial challenge. Efficacious vaccines are 23 
available to reduce the impact of coliform mastitis, but vaccine development for gram-positive 24 
mastitis has not progressed beyond the “promising” stage for decades. Improved diagnostic tools to 25 
identify causative agents and transmission patterns may contribute to targeted use of antimicrobials 26 
and intervention measures. The most important tool for improved uptake of known mastitis 27 
prevention measures is communication. Development of better technical or biological tools for 28 
management of environmental mastitis must be accompanied by development of appropriate 29 
incentives and communication strategies for farmers and veterinarians, who may be confronted with 30 
government-mandated antimicrobial use targets if voluntary reduction is not implemented. 31 
 32 
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INTRODUCTION  36 
The world population is growing and needs increasing amounts of food. We need food for more 37 
people, and we need more food per person as the global increase in average income drives changes 38 
in consumption patterns (Foresight, 2011). In 2007, Wen Jiabao, the then Premier of the People's 39 
Republic of China, said “I have a dream to provide every Chinese, especially children, sufficient milk 40 
each day”. There are an estimated 1.4 billion people in China – a lot of milk will be needed to satisfy 41 
Wen Jiabao’s dream. At the same time, the growing world population puts increasing pressure on 42 
the availability of land and water. Land is needed for farming, for ecosystem services such as climate 43 
regulation, and for human habitation. To mitigate the risks of climate change, use of biofuels has 44 
been advocated. This puts further pressure on the availability of land and water because biofuel 45 
production competes with feed and food production. To satisfy the many and conflicting demands 46 
on our planet, there is a clear need for sustainable intensification of food production, or “producing 47 
more with less” (Foresight, 2011). Reductions in waste, both before and after harvest, are a key 48 
component of sustainable food production. In dairy cattle, mastitis is a major cause of biological 49 
inefficiency or waste, e.g. trough lower yields, increased culling, discarded milk, and impacts on 50 
fertility (Halasa et al., 2007; Seegers et al., 2003). In addition, mastitis affects animal welfare, which 51 
is highly valued in many industrialized countries (Byrd et al., 2017; Tremetsberger et al., 2015). Thus, 52 
there are many reasons to control mastitis in dairy cattle. 53 
Mastitis, inflammation of the mammary gland, is primarily caused by bacterial 54 
intramammary infection (IMI). For control of bacterial infections in human and veterinary medicine, 55 
we often rely on the use of antimicrobials. Antimicrobial use (AMU) may contribute to antimicrobial 56 
resistance (AMR), which is another major societal concern relevant to milk production. The World 57 
Health Organisation (WHO) recently endorsed a global action plan to tackle AMR and published a list 58 
of priority pathogens for research and development of new antibiotics (WHO 2015, 2017a). This list 59 
includes several mastitis pathogens, notably Escherichia coli, Klebsiella (“critical”), and 60 
Staphylococcus aureus (“high priority”). They also produced a list of critically important 61 
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antimicrobials for human medicine, which includes compounds that are used for mastitis treatment, 62 
e.g. 3rd and 4th generation cephalosporins (3/4GC) and fluoroquinolones (“ critical”) (WHO, 2017b). 63 
Societal pressure is increasingly leading to calls for reduced AMU in animal agriculture, including 64 
dairy farming. In response to such pressures, quota or policies to reduce AMU are being proposed or 65 
implemented in several Western European countries (Dorado-García et al., 2016; O’Neill, 2016). 66 
Veterinarians and farmers will need to wean themselves from reliance on antimicrobials for mastitis 67 
control. Control of environmental mastitis without reliance on AMU depends on infection 68 
prevention, whereby host resistance, bacterial load, and contact opportunities between hosts and 69 
pathogens are the key drivers of infection risk. 70 
  In the past few decades, dairy farming in the developed world has changed profoundly 71 
(Barkema et al., 2015). Concomitantly, there has been a major decrease in the prevalence of 72 
contagious mastitis and a relative or absolute increase in the incidence of environmental mastitis. In 73 
this paper we provide an overview of factors influencing the occurrence and control of 74 
environmental mastitis, which we define as mastitis caused by pathogens derived from the 75 
environment rather than from other infected cows in the herd. For many decades, the moniker 76 
“environmental mastitis” has been reserved for a limited number of species and genera, dominated 77 
by coliforms and Streptococcus uberis. We challenge this perception with data showing that many 78 
other pathogens, including S. aureus and Streptococcus agalactiae, can be environmental and argue 79 
that changes in host, pathogen and the environment, including societal and economic pressures, 80 
drive changes in the epidemiology and control of mastitis. Finally, we identify and prioritize gaps in 81 
our current knowledge of environmental mastitis, where further research or product development 82 
may be beneficial to the dairy industry, cattle health and human society.  83 
  84 
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DISEASE IN THE NATURAL HOST 85 
Causative Species and Signs of Environmental Mastitis Environmental mastitis is not a single 86 
disease but rather a disease syndrome with many potential causative agents and many contributing 87 
causes at host and environmental level. A brief description is given of infection- and host-response 88 
patterns for major gram-negative and gram-positive catalase-negative (GPCN) mastitis pathogens. 89 
Mastitis caused by S. aureus or Mycoplasma are described in detail in dedicated papers in this 90 
special issue, and mastitis caused by coagulase negative staphylococci has recently been reviewed 91 
elsewhere (Vanderhaeghen et al., 2015). Algae of the genus Prototheca will not be covered, in part 92 
because it is not clear whether they are environmental or contagious pathogens (Jánosi et al., 2001; 93 
Osumi et al., 2008). In veterinary practice, there is often a perception that severe clinical mastitis 94 
(CM) (abnormalities in milk and mammary gland, accompanied by systemic signs) is primarily caused 95 
by coliform species but severe CM may also be caused by streptococci (Figure 1) or S. aureus (Zadoks 96 
et al., 2000; Tassi et al., 2013). Conversely, mastitis caused by coliform species may be moderate 97 
(abnormalities in milk and mammary gland, no systemic signs), mild (abnormalities in milk only) or 98 
persistently subclinical (no visible signs) (Bradley and Green, 2000; Schukken et al., 2011a). Mild to 99 
moderate forms of clinical mastitis may also be caused by S. agalactiae (Barkema et al., 1998; 100 
Cortinhas et al., 2016). Thus, there is no one-to-one relationship between clinical severity and 101 
causative agent, nor is there a one-to-one relationship between mode of transmission and causative 102 
agent (see Epidemiology). 103 
Gram-negative mastitis Mastitis caused by E. coli is generally transient and disease outcome largely 104 
depends on host factors, e.g. lactation stage (Burvenich et al., 2003), energy balance 105 
(Suriyasathaporn et al., 2000), vitamin deficiency (Smith et al., 1997) and vaccination status (Bradley 106 
et al., 2015a). Antibody-mediated immunity and neutrophil phagocytosis play a major role in the 107 
host response to E. coli mastitis, which may explain why vaccination against E. coli mastitis has been 108 
more successful than vaccination against other mastitis pathogens (Schukken et al., 2011b). 109 
Although most E. coli infections are transient, longitudinal studies with molecular typing of bacterial 110 
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isolates have demonstrated that E. coli infections can be persistent, often with repeated episodes of 111 
CM linked by periods of subclinical infection (Döpfer et al., 1999). Subclinical coliform infections may 112 
start in the dry period and can manifest as CM in early lactation, up to more than 100 days in milk 113 
(Bradley and Green, 2000). In herds with bulk milk somatic cell count (BMSCC) below 250,000 114 
cells/ml more than 50% of early lactation coliform CM were due to dry period infection (Bradley and 115 
Green, 2000). The difference between onset of infection and clinical manifestation of disease has 116 
been attributed to polarization of the immune response and anti-inflammatory signalling during the 117 
dry period (Quesnell et al., 2012; Schukken et al., 2011b). Onset of infection in the dry period leading 118 
to CM in lactation has also been observed for Klebsiella, Citrobacter and Serratia spp. (Bradley and 119 
Green, 2000). For prevention of environmental mastitis, it is important to determine whether CM in 120 
early lactation is due to infections during the dry period or during lactation. Control measures need 121 
to target the relevant infection risks, e.g. poor environmental hygiene or non-use of teat sealants in 122 
the dry period, versus inadequate hygiene or nutrition in lactation. 123 
 The pathophysiology of IMI due to Klebsiella, Enterobacter spp. and non-coliform 124 
Enterobacteriaceae such as Serratia spp. is not n as well-studied as for E. coli but there is a recent 125 
review dedicated to comparative analysis of their pathogenicity and immune response patterns 126 
(Schukken et al., 2012). In experimental studies, Klebsiella elicits more severe clinical signs and a 127 
stronger immune response than E. coli, whereby serum haptoglobin, interleukin (IL)-1 and IL-t 128 
concentrations in serum are indicative of the chance of survival (Hisaeda et al., 2011). On-farm 129 
mortality due to Klebsiella can be high (Ostrum et al., 2008; Schukken et al., 2012). Bacteraemia may 130 
develop in cows with severe acute CM and contributes to mortality (Wenz et al., 2001; Suojala et al., 131 
2013). Bacteraemia may be caused by the mastitis-pathogen or by bacteria from the gut or lung, e.g. 132 
Pasteurella or Salmonella spp. (Wenz et al., 2001). Subclinical and mild clinical manifestations of 133 
Klebsiella mastitis also occur quite commonly (Oliveira et al., 2013; Figure 2). Knowledge of causative 134 
agents of CM can inform management decisions, e.g. around vaccination or hygiene measures (see 135 
Prevention, Detection and Control). 136 
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 Genomic analysis of mammary pathogenic E. coli (MPEC) suggests that the MPEC 137 
phenotype may have arisen from the wider E. coli population on multiple occasions (Richards et al., 138 
2015). Isolates from both transient and persistent E. coli infections are genetically heterogeneous 139 
and there is no consistent genotype or virulence profile associated with either manifestation, making 140 
the existence of an MPEC genotype a matter of debate (Dogan et al., 2012; Richards et al., 2015). 141 
Richards and colleagues (2015) noted that the type VI secretion system (T6SS) was present in all 4 142 
MPEC isolates, compared with a prevalence of 38.6% in non-mammary isolates of E. coli (n = 56) and 143 
Shigella (n = 9) and suggested that further research should be conducted into the role of T6SS. This 144 
was not supported by comparative genomic analysis of E. coli by Kempf and colleagues (2016), who 145 
agreed with Dogan’s conclusion regarding the absence of specific virulence genes. In phenotypic 146 
analysis of E. coli isolates, Kempf’s colleagues identified the ability to resist phagocytosis and to 147 
ferment lactose as features associated with a mammary origin (Blum et al., 2008). Surprisingly, 148 
genes encoding lactose fermentation were not mentioned in the genomic studies on E. coli (Kempf 149 
et al., 2016; Richards et al., 2015). 150 
 For Klebsiella, as for E. coli, the ability to cause mastitis is not linked to any specific clade  151 
but genomic analysis showed that genes associated with lactose fermentation were strongly 152 
overrepresented in isolates from mastitis (26 of 32) compared to those from bovine faeces (3 of 19) 153 
or non-farm sources (Holt et al., 2015). This suggests that that mastitis-causing Klebsiella, like 154 
mastitis-causing E. coli, benefits from the ability to ferment lactose. The lactose operon was 155 
collocated with an iron-enterobactin operon. Thirty bovine isolates carrying both operons were 156 
found in 23 different lineages of K. pneumoniae phylogroups I and II, demonstrating that they are 157 
linked and subject to extensive horizontal transfer (Holt et al., 2015). Interestingly, the ferric 158 
enterobactin receptor FepA was an early target for development of a Klebsiella vaccine (Lin et al., 159 
1999). In dry cow secretion, antibodies against FepA inhibited the growth of all E. coli isolates but 160 
less than half of K. pneumoniae isolates (43%) (Lin et al., 1999). This observation might be explained, 161 
in part, by the fact that the enterobactin gene is chromosomally located in E. coli but largely 162 
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plasmid-borne and hence less consistently present in Klebsiella (Holt et al., 2015; Kempf et al., 2016). 163 
Alternative vaccine targets for Klebsiella mastitis are yet to be identified. 164 
Gram-positive Catalase-negative Cocci In many studies and diagnostic laboratories, all GPCN other 165 
than S. agalactiae are lumped under the badge “environmental streptococci” or “Streptococcus 166 
spp.” (Cameron et al., 2016; Oliveira et al., 2013). Both misnomers cover Streptococci, Enterococci 167 
and Lactococci, among others. The major Streptococci are S. uberis and Streptococcus dysgalactiae, 168 
the major Enterococci are Enterococcus faecium and Enterococcus faecalis, and the main Lactococci 169 
are Lactococcus lactis and Lactococcus garviae (Cameron et al., 2016; Petersson-Wolfe et al., 2009). 170 
The role of Enterococci as causative agents of mastitis has long been recognized  whereas 171 
Lactococcus spp., previously studied as potential tools in mastitis prevention or treatment, have only 172 
recently been recognized as mastitis pathogens in their own right (Plumed-Ferrer et al., 2013; 173 
Rodrigues et al., 2016). The advent of advanced diagnostic methods has aided the recognition of 174 
GPCN species. With the exception of S. uberis, however, relatively little is known about shedding 175 
patterns, pathogenesis and host immune response to those pathogens. A PubMed search of 176 
“[pathogen name] mastitis challenge” yielded 58, 13, 2 and 5 hits for S. uberis, S. dysgalactiae, 177 
Enterococcus and Lactococcus, respectively, with more than 20 experimental challenge studies for S. 178 
uberis, and none or very few for the other species or genera. This reveals a surprising knowledge gap 179 
for S. dysgalactiae. Although its status as environmental versus contagious pathogen may be 180 
debated (Fox and Gay, 1993; Smith et al., 1985), its importance as mastitis pathogen is beyond 181 
doubt, often on a par with or even exceeding the prevalence or incidence of S. uberis (Lundberg et 182 
al., 2013; Sampimon et al., 2009a).  183 
 Within S. uberis, multiple clonal complexes are recognized and virulence is higher for CC5, 184 
which is largely associated with CM, than for CC143, which is predominantly associated with 185 
subclinical mastitis, or CC86, which has been linked to latent infection (Tomita et al., 2008). Strain-186 
specific virulence can be replicated in vivo (Hill 1988; Tassi et al., 2015) and is associated with 187 
differences in uptake and killing by neutrophils or monocytes in vitro (Hill 1988, Tassi et al., 2013). 188 
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There is, however, no obvious association between outcome of infection and gene content (Hossain 189 
et al., 2015). Strain-specific virulence has also been documented for E. faecium (Petersson-Wolfe et 190 
al., 2009). Potential virulence genes underpinning such differences have not been studied in 191 
Enterococci but the genomic tools that have been developed to study virulence factors of S. uberis 192 
mastitis could provide insight into the functional genomics of other GPCN species (Blanchard et al., 193 
2015). As for coliforms, host-characteristics affect the outcome of GPCN infections: cows in early 194 
lactation responded differently to E. faecium challenge than those in late lactation, and a S. uberis 195 
strain that largely failed to cause infection in mid-lactation animals had been isolated from CM at 196 
parturition (Petersson-Wolfe et al., 2009; Tassi et al., 2013). In vitro, macrophages from dry cow 197 
secretion are more active against S. uberis than those from mid-lactation cows, even though S. 198 
uberis infections commonly occur in the dry period (Denis et al., 2006). The role of mammary 199 
epithelium in pathogenesis of S. uberis mastitis is debated and has various been described as linked 200 
to infection outcome (Tassi et al., 2015), largely irrelevant (Leigh, 1999) or sufficiently common and 201 
critical to base vaccine development around it (Almeida et al. 2015; see Vaccines). 202 
 Streptococcus agalactiae is currently not considered as one of the “environmental 203 
streptococci” but we argue that this GPCN species may be of environmental origin with humans 204 
acting as reservoir. Challenge studies comparing the bovine host response to S. agalactiae of human 205 
and bovine origin were published in the early 1980s and are poorly known in the current mastitis 206 
community (Jensen, 1982; Van den Heever and Giesecke, 1980). Inoculation of bovine mammary 207 
glands with S. agalactiae from humans, where it is primarily known as Group B Streptococcus, 208 
results in an acute response characterized by CM with milk losses greater than those observed after 209 
challenge with bovine strains (Jensen, 1982; Van den Heever and Giesecke, 1980). Infections with 210 
human strains are more likely to cure spontaneously than those caused by bovine strain (Jensen, 211 
1982). This, combined with lower levels of bacterial shedding, limits the opportunity for contagious 212 
transmission (Jensen, 1982). Strain specific shedding has also been documented in field studies 213 
(Mahmmod et al., 2015). The observations from experimental challenge studies may explain why CM 214 
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due to S. agalactiae is occasionally observed in low BMSCC herds without apparent within-herd 215 
transmission (Barkema et al., 1998). The authors are aware of similar anecdotal reports from large 216 
dairy herds in the USA, where AMR was described as an additional feature of such uncharacteristic 217 
clinical and epidemiological manifestations of S. agalactiae. Strain typing studies support the 218 
occasional occurrence of human-derived strains in dairy cattle, including the presence of AMR 219 
determinants that are typical of human as opposed to bovine S. agalactiae (Dogan et al., 2005). 220 
 221 
Porte d’entree. For most mastitis pathogens, the teat end is considered the porte d’entree into the 222 
mammary gland.  It has been suggested that presence of minor pathogens (non-aureus 223 
Staphylococci, Corynebacteria) at the teat end may protect against infection with major pathogens 224 
(Reyher et al., 2011). The authors of a recent review (Reyher et al,. 2011) concluded that 225 
observational studies showed no such effect, “whereas challenge studies showed strong and 226 
significant protective effects, specifically when major pathogens were introduced into the mammary 227 
gland via methods bypassing the teat end”. Physical or physico-chemical characteristics of the teat 228 
end may contribute to that discrepancy, such as the amount of keratin present, peak flow rate and 229 
teat canal length (Capuco et al., 1992; Lacy-Hulbert and Hillerton, 1995). In some modern large 230 
herds, e.g. in the High Plains area of the Western USA, milk production is measured per hour rather 231 
than per cow, acre or person. The emphasis on milking speed may potentially contribute to teat-duct 232 
patency and increased risk of environmental mastitis. This could be a factor contributing to the high 233 
incidence of Klebsiella mastitis in the USA compared to Europe. There is almost no evidence on the 234 
role of flow rate and teat end characteristics in susceptibility to gram-negative mastitis. Even less is 235 
known about the role of the teat end microbiota. Teat end microbiota differ between healthy 236 
quarters with or without a history of mastitis (Falentin et al., 2016). Quarters without a history of CM 237 
had higher microbial diversity, more members of the class Clostridia, the phylum Bacteroidetes, and 238 
the order Bifidobacteriales, and fewer members of the classes Bacilli, which includes Staphylococci, 239 
and Chlamydia. Whether such differences are cause or consequence of CM or antimicrobial 240 
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treatment is unknown (Falentin et al., 2016). Further research into the composition and role of teat 241 
end microbiota, the impact of teat disinfectants and antimicrobial treatment, and potential 242 
microbiota manipulations may provide new insight or tools for environmental mastitis control. 243 
 244 
EPIDEMIOLOGY 245 
Pathogen Characteristics Molecular epidemiology studies have been important in elucidating the 246 
range of transmission modes within mastitis-causing pathogen species and it is increasingly clear 247 
that the distinction between contagious and environmental pathogens should be applied at strain 248 
level rather than species level (Gurjar et al., 2012; Zadoks et al., 2011a). Streptococcus agalactiae, 249 
long considered the quintessential contagious pathogen, may originate from humans (Dogan et al., 250 
2005) or faeces (Farre et al., 2017; Jørgensen et al., 2016). Klebsiella pneumoniae, almost exclusively 251 
seen as environmental pathogen, may occasionally spread from cow to cow (Munoz et al., 2007; 252 
Schukken et al., 2011a). In human medicine, there is increasing recognition that most people carry S. 253 
aureus and that patients may become infected with their own strain of the pathogen whilst staying 254 
in the same hospital (Price et al., 2017). Likewise, cows staying on the same dairy farm may become 255 
infected with their own individual or environmental strains of S. aureus (Zadoks et al., 2011a). 256 
Control strategies that reduce contagious transmission do not affect the occurrence of 257 
environmental S. aureus mastitis (Sommerhäuser et al., 2003). The possibility of contagious 258 
transmission of S. uberis was demonstrated with molecular tools more than a decade ago, and it is 259 
now acknowledged that cow-to-cow transmission may be the predominant route of infection in 260 
many dairy herds (Davies et al., 2016; Zadoks et al., 2003). Veterinarians’ and researchers’ insistence 261 
on erroneously classifying S. aureus as contagious pathogen and S. uberis as environmental 262 
pathogen leads to false emphasis on mastitis control methods that may be irrelevant to a farm’s 263 
situation. For example, a major overhaul of the parlour routine will not resolve an environmental S. 264 
aureus mastitis problem (Gurjar et al., 2012).  265 
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Although strain typing has been used in numerous mastitis studies, there is some confusion 266 
around the epidemiological interpretation of such data. Strain heterogeneity is often interpreted as 267 
evidence of environmental mastitis and strain homogeneity is interpreted as evidence of contagious 268 
transmission. The former is correct but the latter is not (Figure 3). Strain homogeneity can result 269 
from contagious transmission or environmental point source infection, as shown for mastitis 270 
outbreaks caused by Pseudomonas aeruginosa (Daly et al., 1999) and Serratia spp. (Muellner et al., 271 
2011). Additional epidemiological investigation and testing of environmental samples can be used to 272 
place molecular data in context (Muellner et al., 2011; Munoz et al., 2007). Few diagnostic 273 
laboratories offer strain typing as a routine method to differentiate between potential 274 
epidemiological scenarios within a herd. When offered, strain typing is currently based on 275 
comparative analysis of multiple isolates from a single herd (Gurjar et al., 2012). To date, there are 276 
no definitive methods to identify a single coliform, streptococcal or staphylococcal isolate as 277 
environmental opportunist or potentially contagious pathogen. For gram-positive mastitis 278 
pathogens, there is some evidence that transmission may be a function of the pathogen, as 279 
observed rates of transmission differ between strains that are present in the same herd (Smith et al., 280 
1998; Zadoks et al., 2003). Host factors such as shedding level or milk leakage may also affect 281 
transmission, as do environmental and herd management factors, including bedding hygiene and 282 
teat disinfection (Munoz et al., 2007; Zadoks et al., 2001). Routine availability of strain typing as a 283 
diagnostic tool and recognition of the non-binary nature of mastitis pathogens could contribute to 284 
improved mastitis control. 285 
 286 
Host Range Most major mastitis pathogens are not host-specific. Streptococcus agalactiae, often 287 
erroneously described as an “obligate intramammary pathogen”, is a commensal in humans, with 20 288 
to 40% of healthy men and women carrying the organism in their urogenital tract, gastro-intestinal 289 
tract or throat (reviewed in Lyhs et al, 2016). Several strands of indirect evidence suggest that milkers 290 
may introduce the pathogen into cattle herds (reviewed in Lyhs et al., 2016).  It also affects fishes and 291 
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can be found in marine, fresh and waste water (reviewed in Delannoy et al., 2013). Within the species 292 
Streptococcus dysgalactiae, two subspecies are recognized, i.e. S. dysgalactiae subsp. equisimilis and 293 
S. dysgalactiae subsp. dysgalactiae. The former is a commensal and pathogen of people but rarely 294 
affects cattle. The latter is a frequent mastitis pathogen, and commonly referred to as S. dysgalactiae 295 
in the veterinary literature (Lundberg et al., 2014). In sheep, S. dysgalactiae subsp. dysgalactiae causes 296 
polyarthritis or joint ill in lambs, but it rarely causes mastitis. S. uberis and E. coli are also common 297 
mastitis pathogens in cattle but relatively rare in sheep (Gelasakis et al., 2015; Zadoks et al., 2014). 298 
Conversely, Mannheimia haemolytica mastitis is common in sheep but not in cattle, whereas S. aureus 299 
is common in both host species (Gelasakis et al., 2015; Zadoks et al., 2011a) and also in people (Price 300 
et al, 2017; Zadoks et al., 2014). The mechanisms underpinning observed differences in host 301 
preference are poorly studied and may provide insights into host-adaptation or virulence factors. Pigs, 302 
dogs and cats may occasionally act as sources of mastitis pathogens, with pigs playing a role in MRSA 303 
transmission (see Socio-economic aspects), and dogs or cats acting as a source of S. canis (Richards et 304 
al., 2012).  305 
 306 
Vectors Mastitis pathogens are rarely vector-transmitted. Insect vectors such as flies and wasps may 307 
play a role in transmission of some mastitis pathogens, notably S. aureus, S. dysgalactiae and 308 
pathogens associated with summer mastitis (Chirico et al., 1997; Yeruham et al., 2002). Vector-borne 309 
mastitis may affect non-lactating cattle but should probably be classed as contagious mastitis 310 
because pathogens are transmitted from host to host by the vectors (Owens et al., 1998). A role of 311 
stable flies in transmission of E. coli mastitis has been suggested but not proven (Castro et al., 2016). 312 
Environmental controls, i.e. insect control, may reduce the risk of vector-borne mastitis but an 313 
investigation of the impact of fly control in heifers on early lactation CM yielded results that 314 
depended on selection of the outcome variable of interest (Green et al., 2007).  315 
 316 
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Reservoirs The major reservoirs for environmental pathogens are unused or used bedding material 317 
and bovine faeces. For example, sawdust is a recognized risk factor for Klebsiella mastitis (Ericsson 318 
Unnerstad et al., 2009; Munoz et al., 2007). Composted bedded pack (CBP) systems and peat have 319 
recently been associated with outbreaks of K. pneumoniae mastitis in Denmark. In those outbreaks, 320 
it is not known whether bedding served as the original source of the pathogen or merely as growth 321 
medium for its amplification. Peat and straw bedding are both recognized as risk factors for S. uberis 322 
mastitis (Ericsson Unnerstad et al., 2009), but S. uberis is also highly prevalent during the pasture 323 
season in the Netherlands and in the pasture-based system of New Zealand (Lopez-Benavides et al., 324 
2007; Olde Riekerink et al., 2007). Due to high cost and lack of availability of traditional bedding 325 
materials, the use of physically separated slurry or recycled manure solids (RMS) as bedding material 326 
has grown in recent years. RMS may be obtained through separation of anaerobic digested manure, 327 
separation of raw manure, or separation of raw manure followed by mechanical drum-composting 328 
(Husfeldt et al., 2012; Leach et al., 2015). Drum-composted manure solids contained no coliform 329 
bacteria prior to use as bedding, in contrast to digested and raw manure (Husfeldt et al., 2012). Even 330 
if composted solids contain no coliforms prior to use, they are a rich source of nutrition for bacteria 331 
and once used, there is no difference in coliform counts between composted, digested or raw 332 
manure (Husfeldt et al., 2012). Control methods may differ between categories of pathogens, both 333 
for  RMS (Leach et al., 2015; Rowbotham and Ruegg, 2016) or CBP (Eckelkamp et al., 2016). Leach 334 
and colleagues (2015) warn that caution is needed when adopting RMS use in Europe, i.e. under 335 
climatic conditions that differ from the dry climates in the USA where its use was developed. 336 
Moreover, they warn that little is known about the impact of RMS use on AMR (Leach et al., 2015). 337 
Dairy farm slurry can be a source of resistant pathogens. For example, ESBL resistant E. coli was 338 
detected in slurry from 41% of herds in a study in The Netherlands (Gonggrijp et al., 2016). With 339 
growing concern about AMR (see Socio-Economic aspects), better understanding of the impact of 340 
manure recycling on both udder health and AMR is needed.  Use of inorganic bedding, e.g. sand, is 341 
recommended to reduce the environmental load of opportunistic pathogens but high loads of E. coli, 342 
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Klebsiella and GPCN cocci have been found in sand bedding (Kristula et al., 2005; Munoz et al., 343 
2006). High bacterial counts can result from on-farm recycling of sand or poor bedding management. 344 
Once mixed with manure, any type of bedding becomes a source of pathogens and the use of sand 345 
may give a false sense of security, leading to poor maintenance of stalls (Figure 4). Barn conditions 346 
rather than bedding type may be the main determinants of bacterial counts (Zehner et al., 1986).  347 
 Faecal shedding has been documented for S. agalactiae (Jørgensen et al., 2016), S. uberis 348 
(Zadoks et al., 2005) and Klebsiella (Munoz e al., 2006) and average faecal prevalence ranges from 349 
5% to 23% and >80%, respectively, with considerable differences between farms. The faecal 350 
prevalence of S. aureus in cattle ranges from 1.4 to 12%, based on testing of faecal swabs 351 
(Dimitracopoulos et al., 1977; Roberson et al., 1994). Faecal contamination turns not just bedding 352 
but also alleys, traffic lanes, water troughs and the outdoor environment into sources of 353 
environmental pathogens. S. agalactiae has been found in milking parlours, alleys, stalls and water 354 
troughs (Jørgensen et al., 2016). S. uberis can be found in bedding, traffic lanes, water troughs, and 355 
the outdoor environment, including soil and grass (Lopez-Benavides et al., 2007; Zadoks et al., 2005). 356 
In the absence of cattle, S. uberis is undetectable, or levels decline rapidly, implying that cattle, and 357 
most likely cattle faeces, are the original source of environmental S. uberis (Lopez-Benavides et al., 358 
2007; Zadoks et al,. 2005). The prevalence of Klebsiella in beds, alleys, on legs and on teats is very 359 
similar to the level of faecal shedding in the same herd, whilst a higher prevalence was detected in 360 
drinking water and a lower prevalence in feed (Zadoks et al., 2011b).The presence of gram-negative 361 
and gram-positive organisms in faeces and drinking water suggests that an oro-faecal transmission 362 
cycle exists for several major mastitis pathogens, including S. agalactiae and K. pneumoniae 363 
(Jørgensen et al., 2016; Zadoks et al., 2011b). With the exception of S. agalactiae, there was 364 
considerable strain heterogeneity within environmental sources of pathogens, which can be 365 
attributed to between and within-animal heterogeneity of strains in faeces (Munoz and Zadoks, 366 
2006; Zadoks et al., 2005). The faecal bacterial load in the environment is a function of initial 367 
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contamination, subsequent amplification and removal and can be managed to reduce the challenge 368 
to the cows’ immune system (see Prevention, Detection and Control). 369 
 370 
SOCIO-ECONOMIC IMPACT AND ZOONOTIC ASPECTS 371 
In addition to societal pressures outlined in the Introduction, there are financial pressures on dairy 372 
farming. When supermarkets charge more for soft drinks, which are essentially bottles of water with 373 
additives, than for a bottle of milk produced by sentient beings, the financial pressures on dairy 374 
production become visible: Not only do we need to produce “more with less” in terms of physical 375 
resources, we also need to produce “more with less” in terms of financial and human resources 376 
(Figure 5). Non-antimicrobial control of bacterial IMI is both labour intensive and knowledge 377 
intensive and the shortage of appropriately trained staff is an increasing problem (Maloney, 2002; 378 
Tipples and Trafford, 2011). In some countries, expensive labour is replaced by automation, e.g. of 379 
milking machines or alley scrapers, whilst dairy care and milk harvesting rely heavily on indigenous 380 
or foreign human labour in other countries (Barkema et al., 2015).  381 
 Direct and indirect economic losses due to mastitis have been estimated (Halasa et al., 2007) 382 
and vary greatly between animals and pathogens. For example, yield losses in heifers are greatest 383 
after E. coli CM and in multiparous animals after Klebsiella CM, and both coliforms have greater 384 
impact on fertility than other pathogen species (Hertl et al., 2014a,b). Yield losses may persist for 385 
months after coliform or GPCN mastitis whilst CM with non-aureus Staphylococci does not cause 386 
reduced production (Hertl et al., 2014a). The association of pathogens with culling risk differs 387 
between heifers and multiparous animals, lactation stages, and number of CM episodes, with 388 
different combinations of factors identifying different pathogen species as being associated with the 389 
highest risk of culling (Cha et al., 2013; Gröhn et al., 2005). Other costs of mastitis are even harder to 390 
quantify and relate to its impact on public perception, notably perceptions around animal welfare 391 
and use of antimicrobials. This creates a dilemma as treatment of mastitis may be necessary for 392 
welfare reasons, and would often involve the use of antimicrobials. 393 
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 Of major concern from a zoonotic perspective are methicillin resistant S. aureus (MRSA) and 394 
extended-spectrum betalactamase (ESBL) producing coliforms. Studies based on data collected 395 
around the millennium (1994 to 2001) showed little evidence for a relationship between use of 396 
antimicrobials for mastitis control and AMR (Erskine et al., 2002; Makovec and Ruegg, 2003). In the 397 
early 21st century, however, we have seen the emergence of MRSA in cattle in Europe and 398 
elsewhere. Molecular evidence suggests that some MRSA, notably MRSA carrying the mecC gene 399 
rather than the more common mecA gene, may have arisen in cattle whereas mecA MRSA probably 400 
originates in other host species (Holmes and Zadoks, 2011). MRSA was first recognized as a cause of 401 
mastitis in dairy cattle in Belgium where it was thought to originate from people (Devriese and 402 
Hommez, 1975). Currently, most MRSA of dairy origin in Belgium and several other European 403 
countries belong to sequence type (ST) 398, which is highly prevalent in pigs (Locatelli et al., 2016; 404 
Vanderhaeghen et al., 2010). Transmission from people or pigs, both of which are environmental 405 
sources from the mammary gland’s perspective, is likely to explain introduction into dairy herds. As 406 
for S. canis, initial introduction from an external source may be followed by within-herd contagious 407 
transmission (Tavakol et al., 2012; Vanderhaeghen et al., 2010). Pig and pig farm numbers are 408 
correlated with the risk of MRSA detection in bulk milk (Locatelli et al., 2016). Proximity to pig farms 409 
was also identified as risk factor for detection of ESBL E. coli in organic dairy farms, albeit based on 410 
slurry samples rather than milk samples from cows with mastitis (Santman-Berends et al., 2017). 411 
Those examples show that the environment within the farm and beyond the farm may contribute to 412 
occurrence of mastitis and AMR. 413 
 ESBL-producing coliforms are rarely identified in bovine mastitis in Europe. In France and 414 
Italy, 0.4% of 1427 mastitis-derived E. coli and Klebsiella isolates and 0.7% of 140 Klebsiella isolates, 415 
respectively, were ESBL-positive (Dahmen et al., 2013; Locatelli et al., 2010). Similarly, in Canada, 416 
ESBL was not detected among 394 E. coli and 139 Klebsiella isolates from bovine milk (Saini et al., 417 
2012). By contrast, in China, almost a quarter of E. coli isolates from bovine mastitis were ESBL-418 
producers (Ali et al., 2016). In the UK and The Netherlands, presence of ESBL-coliforms has been 419 
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linked to presence or use of 3/4GC in waste milk and slurry (Gonggrijp et al., 2016; Randall et al., 420 
2013). Despite the low prevalence of ESBL-producers among mastitis pathogens in Western 421 
countries, the association between 3/4GC use and ESBL-prevalence on dairy farms together with 422 
WHO concerns about use of those compounds in animals will in all likelihood limit their availability 423 
as mastitis treatment products. In the USA, extra-label use of 3/4GC was banned (Federal Drug 424 
Administration, 2012). Considering that cephalosporins and fluoroquinolones are the only 425 
compounds with some evidence for beneficial effects in treatment of coliform mastitis (Schukken et 426 
al., 2011a; Suojala et al., 2013), restrictions on their use make prevention of environmental mastitis 427 
even more important. 428 
 429 
PREVENTION, DETECTION AND CONTROL 430 
Biosecurity External biosecurity, i.e. prevention of introduction of pathogens into the herd, is of 431 
limited effect for environmental mastitis because most environmental mastitis pathogens are part of 432 
the normal faecal flora of dairy cows. Bedding materials and health care products may be a source of 433 
pathogens, as described before for Klebsiella in sawdust and Pasteurella in teat wipes. Presence of 434 
pathogens in a health care product doesn’t necessarily indicate that this product was an external 435 
source of pathogens. In a cluster of Serratia outbreaks, farm-specific strains of the pathogen were 436 
identified, and the outbreaks were associated with unhygienic handling of teat dip, resulting in 437 
contamination with Serratia and subsequent growth (Muellner et al., 2011). In Denmark, movement 438 
of cattle from S. agalactiae positive herds was not allowed until 2005 for reasons of external 439 
biosecurity. There was no association, however, between animal movements and a change to S. 440 
agalactiae positive herd status (Mweu et al., 2012, 2014). This supports the notion that S. agalactiae 441 
may be derived from non-bovine, i.e. environmental, reservoirs.  442 
 Measures to reduce bacterial exposure can be taken in the milking parlour and elsewhere. In 443 
Europe, use of pre-dips containing disinfectants to reduce bacterial load prior to milking is rare or 444 
even prohibited, whilst its use is common in the USA. Regardless of whether a wet (pre-dip used) or 445 
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dry (no pre-dip used) pre-milking routine is adopted, it is important to evaluate the effect of the 446 
procedure. Scoring tools for cow, udder and teat cleanliness have been developed to assist with this 447 
task and their use has demonstrated an association between dirty udders and risk of new infection 448 
(Dohmen et al., 2010) or high bacterial counts on teats (Guarin et al., 2017; Munoz et al., 2008). 449 
Moreover, it has been shown that the efficacy of pre-milking teat disinfection is lower for dirty teats 450 
than for clean teats (Munoz et al,. 2008; Zdanowicz et al., 2004). Scoring systems have also been 451 
developed for teat-end callosity or hyperkeratosis (Shearn and Hillerton, 1996). In a small study (135 452 
cows), teat end hyperkeratosis was not associated with the risk of mastitis but a large study (1,667 453 
cows) showed that severe hyperkeratosis is associated with increased risk of E. coli or S. uberis CM, 454 
and moderate hyperkeratosis with increased risk of E. coli CM (Breen et al., 2009; Zoche-Golob et al., 455 
2015). Bacterial loads of both organisms are higher in teat ends with hyperkeratosis than in those 456 
without, providing a plausible biological mechanism for the observed association (Paduch et al., 457 
2012). Hyperkeratosis is associated with the duration of milking, and particularly with overmilking, 458 
which may be an issue in large parlours if automated cluster removal is not used or settings are 459 
incorrect (Edwards et al., 2013). Thus, although milking machine settings and parlour routines are 460 
primarily associated with contagious mastitis, they do also impact on the risk of environmental 461 
mastitis. With the introduction of automated milking systems (AMS), the milking frequency is 462 
increased, particularly for high yielding cows. This may be beneficial, through frequent removal of 463 
bacteria and replenishment of somatic cells in the mammary gland, or harmful due to frequent 464 
opening of the teat canal. Milk leakage is more common in cows milked by AMS than in a milking 465 
parlour, particularly for cows with high milk flow (Klaas et al., 2005; Persson-Waller et al., 2003). This 466 
could lead to higher risk for the cow itself, or for other cows in the herd if the cow leaks milk with 467 
high bacterial loads (Munoz et al., 2007). Although consensus on udder health benefits may not 468 
exist, AMS are gaining ground.   469 
Tools to manage bacterial counts in bedding include bedding replacement and the use of 470 
bedding conditioners. Both alkaline and acidic conditioners have been used successfully to modify 471 
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coliform and streptococcal counts on cow mattresses (Kristula et al., 2008) and in sawdust (Paduch 472 
et al., 2013; Proietto et al., 2013). When using lime, both positive and negative effects were 473 
observed at teat level, i.e. a reduction of bacterial counts as well as damage to teat skin (Kristula et 474 
al., 2008; Paduch et al., 2013). With acidifiers, neither positive nor negative effects were observed 475 
(Kristula et al., 2008; Proietto et al., 2013). The effect of acidifiers is time limited. In comparison with 476 
untreated control bedding, bacterial counts in treated sawdust or recycled manure were reduced on 477 
day 1 after addition, but not on day 2 or day 6, suggesting that daily addition of conditioner may be 478 
needed to maintain reduced bacterial counts (Hogan et al., 2007). When RMS are used as bedding 479 
material, either as top layer on mattresses or as deep layer, daily replacement reduces coliform 480 
counts, specifically for Klebsiella but the same management strategy increased streptococcal counts 481 
(Sorter et al., 2014). In CBP, coliform and streptococcal counts differ from each other in their 482 
association with cow density, ambient or internal temperature and carbon:nitrogen ratio (Black et 483 
al., 2014; Eckelkamp et al., 2016). There is no single optimal method to choose or manage bedding 484 
to reduce exposure to all types of environmental pathogens (Leach et al., 2015; Rowbotham and 485 
Ruegg et al., 2016).  486 
 Infection risk in dry cows is predominantly driven by herd and management rather than cow 487 
factors (Bradley et al., 2015b; Green et al., 2007). Green and colleagues (2007) grouped risk factors, 488 
which include protective factors, by stage of the dry period, i.e. the drying off process itself, early dry 489 
period, late dry period or transition period, and finally the calving period. For cows that were housed 490 
during the dry period, protective effects were observed for good drainage in the early dry-cow 491 
cubicle accommodation, use of mattresses on dry-cow and transition cow cubicle surfaces, 492 
disinfection of cubicle bedding for the early dry period or the close-up groups, scraping of the feed 493 
and loaf area at least once daily, and bedding of cubicles at least once daily. Dry cows housed in 494 
straw yards, where disinfection is not an option, and transition cows that were housed with milking 495 
cows were at increased risk of CM in early lactation (Green et al., 2007). Although this analysis was 496 
based on detection of CM in early lactation rather than on detection of IMI during the dry period, 497 
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the association between dry period IMI and lactational CM (see Disease in the Natural Host) suggests 498 
that prevention of dry period IMI through reduced exposure to pathogens explains the observations, 499 
at least in part. For cows that were out on pasture during the dry period, a pasture rotation method 500 
of 2 weeks of grazing by dry cows followed by 4 weeks without grazing reduced the risk of early 501 
lactation CM (Green et al., 2007). This may be due to a reduction in bacterial load on pasture in the 502 
absence of cattle, as demonstrated for S. uberis (see Reservoirs).  Specific advice on straw yard 503 
management, which was used to house more than half of the cattle in the study, could not be 504 
derived from the data (Green et al., 2007). 505 
  506 
Detection Diagnostics can be used to detect mastitis, i.e. mammary gland inflammation, or IMI, i.e. 507 
pathogen presence. Inflammation can be detected based on somatic cell count (SCC), electrolytes, 508 
enzymatic markers or acute phase proteins (Viguier et al., 2009; Pyörälä et al., 2011). As methods for 509 
pathogen detection become more sensitive, the ability to differentiate between pathogen-positive 510 
samples with and without evidence of inflammation becomes increasingly important, particularly 511 
when testing is conducted to inform treatment decisions, bearing in mind the societal pressure to 512 
reduce AMU. Detection of IMI has traditionally been based on culture but there is a wide range of 513 
opinions on how to interpret culture results (Dohoo et al., 2011). Species identity of cultured 514 
bacteria can be confirmed with phenotypic or genotypic methods (Zadoks and Watts, 2009). 515 
Phenotypic identification using biochemical profiles is unreliable for many mastitis pathogens, 516 
including Klebsiella and Staphylococcus spp. (Munoz et al., 2007; Sampimon et al., 2009b). Modern 517 
phenotypic testing is increasingly based on proteomics, notably matrix-assisted laser desorption 518 
ionization time-of-flight mass spectrometry analysis (Cameron et al., 2017; Schabauer et al., 2014). 519 
Its application directly to milk samples may be possible but only at high bacterial concentrations 520 
(Barreiro et al., 2017). PCR or sequencing of housekeeping genes for species detection or 521 
identification are commonly applied to milk samples (PCR) and cultured isolates (sequencing), 522 
respectively, although both methods can be used for both sample types. PCR-based detection of 523 
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mastitis pathogens in milk has been used commercially for almost a decade (Koskinen et al., 2009) 524 
and is very popular in Europe’s Nordic countries whilst uptake is slower elsewhere. PCR-panels 525 
targeting few or many pathogens are available, and pathogens may be detected at species or genus-526 
level. Detection of blaZ, encoding penicillin-resistance, is also possible but PCR may not be sufficient 527 
to determine whether a staphylococcal resistance gene is present in S. aureus or other staphylococi 528 
(Koskinen et al., 2009; Virgin et al., 2009). For PCR, as for culture, interpretation of results is subject 529 
to debate. The increased sensitivity of PCR, which detects bacteria that are non-viable, viable but 530 
difficult to culture or easy to culture, is an advantage over culture, which only detects the last 531 
category. However, increased sensitivity may be accompanied by decreased specificity, e.g. positive 532 
PCR-results due to sample contamination (Koskinen et al., 2010). Moreover, work on milk microbiota 533 
has shown that several mastitis-causing organims are commonly detected in healthy mammary 534 
glands (Oikonomou et al., 2012). The microbiota is the totality of bacterial species present based on 535 
culture-independent analysis of 16S rDNA sequences. Its composition and role in the mammary 536 
gland has recently been reviewed (Addis et al., 2016). Crucially, microbiota studies suggest that 537 
mastitis should probably not be attributed to intramammary infection of a normally sterile organ but 538 
to dysbiosis in a gland that has a highly diverse microbiota when it is healthy. Further insight into 539 
milk microbiota may contribute to new mastitis control tools.  540 
A key component of discussions about diagnostics is their intended use. Satisfactory results 541 
in decision-making around targeted versus blanket antimicrobial DCT have been made using records 542 
of SCC and CM, without knowledge of pathogen presence or microbiota composition (Scherpenzeel 543 
et al., 2016). In this situation, the cost of pathogen detection is unlikely to be justifiable. By contrast, 544 
on-farm culture to inform treatment decisions for lactational CM has recently gained popularity 545 
because it allows for a reduction in diagnostic turn-around-time and antimicrobial use (Lago et al., 546 
2011a; Mansion-de Vries et al., 2014). Treatment decisions, and hence the utility of diagnostics, 547 
hinge on treatment options, which may change over time. Currently, they are predicated on the 548 
premise that antimicrobial treatment is justified for gram-positive mastitis but not for culture-549 
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negative mastitis or mild to moderate gram-negative mastitis (see Treatment). Possibly of greater 550 
importance for test-uptake is farmer perception of what constitutes a useful test. In the 551 
Netherlands, 34% of farmers submit milk samples from CM to a diagnostic laboratory, whereas 71% 552 
would consider use of an on-farm test, depending on the time-to-result (Griffioen et al., 2016). A 553 
relatively novel mastitis-diagnostic with potential for short time-to-result is loop-mediated 554 
isothermal amplification (LAMP). LAMP-primers are available for S. aureus (Sheet et al., 2016) and 555 
major streptococci (Bosward et al., 2016; Wang and Liu, 2015) and implementation as pregnancy-556 
test-like lateral flow device is possible (Cornelissen et al., 2016). A major challenge for on-farm 557 
molecular detection of pathogens or AMR-genes is the large number of bacterial species and 558 
resistance genes that may be present in milk or mastitis pathogens. There is a single penicillin-559 
resistance gene in S. aureus, which is covered by commercially available PCR, but there are multiple 560 
categories of ESBL-genes in coliforms (blaSHV, blaTEM and blaCTX-M ESBL), with multiple clusters of 561 
blaCTX-M  genes (e.g. blaCTX-M-1, blaCTX-M-2 and blaCTX-M-9) and multiple genes within each cluster (Trang et 562 
al., 2013). How best to use diagnostics to inform case or herd management is a key question for 563 
further research, whereby markers of inflammation, infection and AMR should be considered, as 564 
well as technological, biological and socio-economic aspects. 565 
 566 
Treatment Recommendations for CM treatment have been reviewed relatively recently, considering 567 
antimicrobial treatment (Roberson, 2012) and non-steroidal anti-inflammatory drugs (Leslie and 568 
Petersson-Wolfe, 2012). Pathogen-specific reviews are available for S. aureus (Barkema et al., 2006), 569 
E. coli (Suojala et al., 2013) and S. uberis (Zadoks, 2007), but not for Klebsiella or S. dysgalactiae. The 570 
probability of cure for S. dysgalactiae mastitis was lower than for S. uberis mastitis in New Zealand 571 
(McDougall et al., 2007a,b) whereas the opposite was true in the USA and Europe (Deluyker et al., 572 
2005; Oliver et al., 2004), probably reflecting differences between dairy farming systems in herd 573 
management and mastitis epidemiology. Several studies suggest that Klebsiella mastitis does not 574 
respond to treatment as well as E. coli mastitis (Schukken et al., 2011a, 2012) and many 575 
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veterinarians and farmers would confirm this from personal experience (Ostrum et al., 2008). In one 576 
study, the reported probability of cure was similar for Klebsiella and E. coli cases but recurrence of 577 
CM and removal from the herd were more likely after Klebsiella mastitis (Oliveira et al., 2013). For 578 
mild to moderate coliform CM, there is fairly broad consensus that treatment has limited impact on 579 
the probability of cure (Hogan and Smith, 2003; Roberson, 2012; Suojala et al., 2013). The use of the 580 
3/4GC ceftiofur and cefquinome, however, improved treatment outcomes in comparison to 1st 581 
generation cephalosporins or no treatment, respectively (Schukken et al., 2011a, 2013). This adds 582 
complexity to the debate because it suggests that antimicrobial treatment of mild to moderate 583 
coliform mastitis may be beneficial, contradicting the prevailing paradigm. Others, however, did not 584 
observe a significant effect of ceftiofur treatment on clinical or bacteriological cure of E. coli mastitis 585 
(Ganda et al., 2016a). Moreover, the use of 3/4GC in farming, is strongly discouraged by WHO and 586 
several veterinary professional organizations (see Socio-economic and zoonotic aspects). In the 587 
authors’ opinion, the arguments against use of 3/4GC for treatment of mild to moderate CM 588 
outweigh the arguments in favour. 589 
Building on the desire to reduce AMU and the notion that antimicrobial treatment is likely to 590 
be beneficial for gram-positive mastitis but not for culture-negative mastitis or mastitis caused by 591 
gram-negative bacteria, Mycoplasma, Prototheca or yeast, the use of culture-based treatment 592 
decisions for mild to moderate CM has been advocated (Roberson 2012; Suojala et al., 2013). Severe 593 
cases of CM, i.e. those with systemic signs, should always be treated for the sake of cow welfare and 594 
to increase the likelihood of survival, and this may include systemic treatment (Suojala et al., 2013). 595 
Whether systemic antimicrobial treatment exerts its effect through clearance of IMI or through 596 
treatment of the bacteraemia that may accompany acute severe CM is not clear (Wenz et al., 2001). 597 
In the absence of systemic signs, treatment decisions for CM can be delayed for 24 hours without 598 
negative consequences for the animal. In that time, information on the causative pathogen can be 599 
generated. In North America, this is largely done through on-farm culture (Lago et al., 2011b; Ganda 600 
et al., 2016b). Elsewhere, this system that has not been adopted widely yet although methods for 601 
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on-farm culture have been in evaluated in Europe (Mansion-de Vries et al., 2014; Viora et al., 2014) 602 
and Africa (Gitau et al., 2013). Alternative approaches include off-farm testing with 24-hr turn-603 
around, which is rarely offered by mastitis diagnostic laboratories, and use of molecular methods, 604 
which are not available in on-farm format yet. On-farm culture methods use agar plates (Ganda et 605 
al., 2016b; Royster et al., 2014) or Petri-films (McCarron et al., 2009) that include selective 606 
supplements to allow for culture of subsets of isolates only, e.g. total bacterial, gram-negative , 607 
staphylococcal or GPCN growth. In the largest field study to evaluate the outcome of culture-based 608 
treatment, a significant reduction was observed in AMU (from 100% of CM cases treated with 609 
antimicrobials to 44%) without a significant impact on milk discard, clinical or bacteriological cure, 610 
new infections, SCC, milk yield or lactational survival (Lago et al., 2011a, b). Thus, there were 611 
benefits in the form of reduced AMU and cost-savings without demonstrable disadvantages of 612 
culture-based treatment. The argument could be made that the absence of negative effects in such 613 
field studies is due to lack of power rather than true absence of negative impacts and that on-farm 614 
culture should not be advocated. The counterargument would be that negative impacts would have 615 
been limited if they were not measurable and that the benefits of this approach outweigh the costs, 616 
particularly when restrictions on AMU are in place.  617 
 The incidence of environmental mastitis is particularly high around and during the dry period 618 
and parturition, when major changes occur in the cow’s physiological, endocrinological and 619 
immunological status (Bradley et al. 2015b; Schukken et al., 2011b). To prevent new IMI during the 620 
dry period, farmers commonly use antimicrobial DCT, which was originally developed for long-term 621 
treatment of existing IMI without the need to discard milk. DCT can be used for all cows, known as 622 
blanket DCT (bDCT), or for selected cows or quarters only (sDCT). Studies comparing bDCT versus 623 
sDCT were published as far back as the 1970s (Rindsig et al., 1978). Then, as in subsequent studies, 624 
sDCT was as effective at eliminating existing IMI as bDCT, but the risk of new infections was higher 625 
with sDCT (Rindsig et al., 1978; Schukken et al., 1993). For decades, the benefits of bDCT to cow 626 
health and welfare (i.e. the reduced risk of new infections) were thought to outweigh the risks in 627 
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terms of AMR in many parts of Europe, with the exception of the Nordic countries where sDCT is the 628 
norm (Østerås et al., 1999). In Denmark, DCT can only be administered after a case of CM within 30 629 
days of dry-off or after detection of a pathogen in a milk sample, putting greater emphasis on clinical 630 
and microbiological criteria than on SCC (Bennedsgaard et al., 2010). Increasingly, other European 631 
countries, e.g. the UK and The Netherlands, now no longer considered bDCT advisable or acceptable 632 
because of concerns over AMR (Biggs et al., 2016; Scherpenzeel et al., 2014). To select cows for DCT, 633 
a wide range of criteria has been considered, including SCC, CM and culture results for part or all of 634 
the current and/or previous lactations (Biggs et al., 2016; Cameron et al., 2014). One of the most 635 
simple criteria was used in a study of 97 herds in The Netherlands, where DCT was not used in cows 636 
that had low SCC at the last milk recording at dry off (SCC <250,000 cells/ml for multiparous cows 637 
and <150,000 cells/ml for primiparous cows), without consideration of SCC or CM data from 638 
previous time points and without pathogen detection. Despite an increase in CM and associated 639 
antimicrobial treatment in animals that did not receive DCT, total antibiotic use related to mastitis 640 
was reduced by 85% using this approach (Scherpenzeel et al., 2014). This demonstrates the 641 
feasibility of reduced AMU if we are willing to accept the impact on cow health and welfare.  642 
To prevent new IMI in non-lactating animals, internal (Huxley et al., 2002) and external (Lim 643 
et al., 2007) teat-sealants and teat-dips (Lopez-Benavides et al., 2009) have been evaluated. 644 
Originally developed in the 1970s, internal sealants did not receive much attention in Europe until 645 
the 21st century (Huxley et al., 2002). They have subsequently been used in combination with 646 
antimicrobial DCT or as an alternative to antimicrobial DCT. Current teat-sealants do not contain 647 
compounds that treat existing IMI, but there is potential to combine them with immune-modifiers 648 
that speed up mammary gland involution or with a disinfectant such as chlorhexidine to reduce the 649 
risk of new infections (Compton et al., 2014; Lanctôt et al., 2017). Whether such modifications 650 
provide any benefit over current internal teat-sealants remains to be demonstrated in field studies. 651 
Based on  meta-analysis of 16 studies on internal teat-sealants, Rabiee and Lean (2013) reported a 652 
reduction in new dry-period IMI by 25% in studies with a positive control (antimicrobial treatment) 653 
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and by 73% in studies with a negative control (no treatment), while CM was reduced by 29% and 654 
48%, respectively. No effect on SCC or linear score was detected.  The adoption of sDCT at national 655 
or herd-level is influenced by the attitudes of farmers, veterinarians, the public and policy makers 656 
(Higgins et al., 2017; Scherpenzeel et al., 2016). Knowledge alone is not enough, as many mastitis-657 
related management practices that are generally considered to be important by experts are not 658 
widely used by farmers (Down et al., 2016).  In recent years, evidence-based decision-making by 659 
veterinarians and communication of health-management advice have become topics of study in 660 
their own right (Higgins et al., 2016; Jansen and Lam, 2012). Involvement of farmer discussion 661 
groups may play an important role in empowering farmers and promoting udder health through 662 
hygiene measures when reducing use of antimicrobials in lactating and dry cows (Bennedsgaard et 663 
al., 2010). Whilst there is a need for development of better technical or biological tools for 664 
management of environmental mastitis, the importance of communication and incentives to 665 
support uptake of such tools must not be underestimated. 666 
 667 
Vaccination Mastitis vaccine-development has focussed primarily on E. coli, S. uberis and S. aureus. 668 
Criteria for evaluation of vaccination success include prevention or reduced severity of CM, reduced 669 
milk loss, reduced mortality and, for S. aureus, improved chances of cure and reduced transmission 670 
(Schukken et al., 2014; Smith et al., 2006).  Contagious transmission of S. aureus can largely be 671 
prevented through good herd management (Sommerhäuser et al., 2003) so vaccination is 672 
particularly relevant for prevention of environmental S. aureus. Attempts to develop S. aureus 673 
mastitis vaccines started in the 1960s but products on the market today are still not satisfactory 674 
(Landin et al., 2015). In the foreseeable future, the dairy industry cannot rely on the magic bullet of 675 
vaccination for reduced AMU and improved mastitis control. Because of space constraints, we refer 676 
to recent reviews for further discussion of staphylococcal vaccines (Pereira et al., 2011) and general 677 
aspects of mastitis vaccine development (Barathan and Mullarky, 2011; Erskine, 2012), whilst 678 
providing a brief discussion of mastitis vaccines for E. coli and GPCN cocci. 679 
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 Vaccination against E. coli mastitis is commonly used in the USA (Erskine, 2012) and has 680 
recently been introduced in Europe. The effect of vaccination with a core J5 E. coli vaccine is probably 681 
largely based on antibodies, as reviewed recently, and cellular immunity may contribute (Schukken et 682 
al., 2011b). Effects of vaccination include reduced severity of mastitis and reduced yield losses, which 683 
is sufficient to offset the cost of vaccination and provides an estimated 2.56:1 return on investment 684 
(Bradley et al., 2015a; Schukken et al., 2011b). Although marketed as E. coli vaccine, the J5-vaccine 685 
may provide some protection from culling among cows with Klebsiella mastitis (Wilson et al., 2007). It 686 
is possible that this effect, as well as the observed reduction in severity of all coliform CM, is mediated 687 
through the systemic pathogenesis of severe coliform mastitis (Erskine, 2012). Vaccination does not 688 
reduce the negative impact of CM on reproduction, nor the overall number of CM cases (Wilson et al., 689 
2007, 2008). The failure of current J5-vaccines to reduce incidence of E. coli IMI is their major limitation 690 
and efforts are underway to enhance infection prevention through intramammary as opposed to 691 
systemic vaccination (Pomeroy et al., 2016). Intramammary immunization may trigger mucosal 692 
immunity, and targeting mucosal immunity is seen as the next battle in development of mastitis 693 
vaccines (Bharathan and Mullarky, 2011). Meanwhile, use of J5-vaccines should be adapted to 694 
individual herd needs (Erskine, 2012). 695 
Whereas production of opsonising antibodies to promote neutrophil uptake and killing 696 
underpinned the success of current J-5 vaccines against E. coli mastitis, it was recognized several 697 
decades ago that this approach is unlikely to be successful for S. uberis because increased antibody 698 
levels did not translate into increased opsonic activity (Hill et al., 1994). Alternative approaches to 699 
vaccine development have been explored since, including attempts to produce antibodies that 700 
would interfere with the metabolic needs of the bacteria and bacterial growth, e.g. by binding 701 
plasminogen activator A (PauA) (Leigh, 1999).  Others have focussed on production of antibodies 702 
that would interfere with binding of S. uberis to mammary epithelial cells, which is mediated by the 703 
S. uberis adhesion molecule (SUAM; Almeida et al., 2015; Prado et al., 2011). Antibodies induced 704 
through vaccination with recombinant SUAM inhibit adherence and internalization of S. uberis into 705 
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mammary epithelial cells in vitro but the importance of this mechanism is debated (Prado et al., 706 
2011, Günther et al., 2016). Although pauA and sua genes are highly prevalent and highly conserved 707 
across strains of S. uberis (Perrig et al., 2015), mastitis can be caused by strains that are negative for 708 
pauA or contain frame-shift mutations in sua, emphasizing the challenges posed by heterogeneity of 709 
the species (Gilchrist et al., 2013; Tassi et al., 2015). In addition to bacterial replication and adhesion, 710 
the role of mononuclear leucocytes has been a focus of S. uberis vaccine development. Vaccination 711 
with S. uberis enhances the proliferative response of peripheral blood lymphocytes to S. uberis 712 
antigens and induces an antigen-specific cytotoxic effect against blood monocytes/macrophages 713 
that have phagocytosed S. uberis (Hill et al., 1994; Wedlock et al., 2014). It is hoped that better 714 
understanding or manipulation of the cellular immune response to S. uberis may contribute to 715 
successful vaccine development (Denis et al., 2011; Schukken et al., 2011b), but it remains a 716 
challenge to activate and harness the cell-mediated arm of the immune response in the unique 717 
immunological environment of the mammary gland (Bharathan and Mullarky, 2011). 718 
Attempts to develop vaccines against S. agalactiae mastitis were described in the early 70s 719 
(Johnson and Norcross, 1971). Because of the successful control of contagious transmission of S. 720 
agalactiae, there has been little incentive for vaccine development in the Western world. Elsewhere, 721 
e.g. in China, prevalence of S. agalactiae is still high, and S. agalactiae mastitis vaccine development 722 
is of renewed interest. Preliminary studies in mouse models show some promise (Liu et al., 2017) 723 
but the route from “fiction” (possibility) to “fact” (realization) is often a long one for mastitis 724 
vaccines (Yancey, 1999). Like research into pathophysiology and epidemiology, research into vaccine 725 
development for S. dysgalactiae is largely neglected. Encouraging preliminary reports on reduction 726 
of S. dysgalactiae infection in a dry cow challenge model through use of the surface receptor protein 727 
GapC have not led to a vaccine, even though there were hopes that such a vaccine could provide 728 
cross-protection to S. dysgalactiae, S. agalactiae and S. uberis  (Bolton et al., 2004; Perez-Casal et al., 729 
2004). More recently, the polysaccharide envelop of S. dysgalactiae has been investigated as a 730 
potential vaccine target, starting with stereocontrolled synthesis of a tetrasaccharide repeating unit 731 
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coupled to a T-cell stimulating immunogen (Ghosh et al., 2016). It will be interesting to see whether 732 
involvement of additional disciplines, such as chemistry, can bring the dream of gram-positive 733 
mastitis vaccines closer. 734 
 735 
CONCLUSION 736 
 737 
In recent decades, there have been major changes in dairy farming and in the distribution of mastitis 738 
pathogens. Contagious transmission of mastitis can be controlled through good milking parlour 739 
hygiene, identification, treatment or culling of infected animals, and tools that reduce the 740 
probability of transmission after contact, such as teat disinfectants. The major impediment to 741 
successful implementation of those tools is the binary classification of bacterial species as 742 
contagious or environmental when in reality many bacterial species, notably S. aureus and S. uberis, 743 
can be transmitted in multiple ways. This insight has been derived from molecular studies, which 744 
allowed for strain typing of mastitis pathogens. Use of such methods as part of mastitis diagnostics 745 
could contribute to targeting of transmission prevention measures. Improved targeting is also 746 
needed for mastitis treatment to meet societal demands for the maintenance of good animal 747 
welfare with reduced use of antimicrobials, particularly highest priority antimicrobials such as 3rd 748 
and 4th generation cephalosporins. Targeted or selective treatment of dry cows has been the norm in 749 
Nordic countries and is increasingly adopted elsewhere in Europe. There is a need for better tools 750 
and education on selection of cows for treatment, whereby both under- and overtreatment should 751 
be avoided. Selective treatment is also applied to clinical mastitis in lactation, where treatment 752 
decisions are guided by on-farm cultures methods that have been developed and evaluated in the 753 
past decade. Improved methods for on-farm diagnostics with shorter time-to-result could promote 754 
uptake of such approaches beyond North America. Less progress has been made in vaccine 755 
development. Despite major research effort, currently available mastitis vaccines provide proven 756 
protection to damage resulting from coliform mastitis but efficacy of gram-positive mastitis vaccines 757 
31 
 
is lacking or debated at best. Vaccine development is hampered by the heterogeneity of mastitis-758 
causing bacteria and by the unique immunological environment of the mammary gland. Existing 759 
tools to enhance host resistance to mastitis, such as breeding, nutrition and prevention of teat end 760 
keratosis, continue to be important. A new area of science that has not been explored or exploited 761 
fully is the study of microbiota. Microbiota studies suggest that mastitis should possibly not be seen 762 
as intramammary infection of a sterile organ but as dysbiosis in the mammary gland. Manipulation 763 
of the microbiota of teats and mammary glands may provide new tools for prevention or correction 764 
of such dysbiosis. Reduction of exposure to environmental pathogens is a key component of 765 
environmental mastitis prevention. With changes in farm sizes and systems, mechanisation, labour 766 
force and use bedding materials, there is a need for better understanding of how pathogen 767 
accumulation can be prevented through management of the environment and the work force. In 768 
doing so, not only bedding material but also the remainder of the indoor environment and the 769 
outdoor environment need to be considered. Last but possibly most importantly, technological or 770 
biological knowledge, tools and innovations need to be supported by appropriate communication 771 
and socio-economic incentives to enhance their uptake. Based on the above, three priority areas for 772 
further research are proposed: 773 
 774 
1. Improved diagnostic tools for evidence-based targeting of antimicrobial treatment and 775 
transmission prevention measures; 776 
2. Tools to monitor and manage bacterial exposure in the dairy cow environment and host 777 
resistance to such exposure, e.g. through manipulation of the cow’s  microbiota. 778 
3. Communication strategies and socio-economic incentives to influence knowledge and belief 779 
systems of veterinarians and farmers and to promote uptake of existing and new mastitis control 780 
tools.  781 
 782 
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Without use, no tool will support the sustainable intensification of dairy production that is needed to 783 
satisfy the growing demand from the world’s human population.   784 
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 1324 
Figure 1. Severe clinical mastitis characterized by abnormalities in milk (bottom right panel), 1325 
mammary gland (left panel) and behaviour (top right panel) due to Streptococcus uberis infection. 1326 
Photos: RN Zadoks. 1327 
  1328 
55 
 
 1329 
Figure 2. Herd-specific proportional distribution of mild to moderate cases of mastitis attributed to 1330 
gram-negative pathogens. Black = Enterobacter cloacae; Off-white = Escherichia coli; Grey = 1331 
Klebsiella spp. Number (n) of cases per herd shown in brackets. (Data: Schukken et al., 2011a; Herd D 1332 
(n = 4) not shown). 1333 
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 1335 
Figure 3. Modes of transmission (Left: contagious; Centre: environmental point source; Right: 1336 
heterogeneous environmental source) and resultant patterns of strain distribution (Left, Centre: 1337 
homogeneous; Right: heterogeneous), demonstrating that strain heterogeneity is proof of 1338 
environmental origin of mastitis pathogens but homogeneity is not proof of contagious transmission. 1339 
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 1341 
Figure 4. Faecal contamination is a major source of exposure to environmental pathogens regardless 1342 
of the use of sawdust (left), straw (right) or other bedding material. Photos: RN Zadoks. 1343 
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 1345 
 1346 
Figure 5. “Amazing value milk”, produced by sentient beings but sold at a lower price than soft 1347 
drinks, illustrating financial pressures on the dairy industry. If the soft drinks had not been on sale, 1348 
they would have cost more than twice as much as milk. Photos: RN Zadoks.  1349 
